{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"17"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"45"}],"units":"Participants"}],"description":"Complete response (CR) requires all of the following:\n\n* Disappearance of monoclonal protein by both protein electrophoresis and immunofixation studies from the blood and urine\n* \\<5% plasma cells in the bone marrow\n* Disappearance of soft tissue plasmacytomas\n\nStringent complete response (sCR) requires all of the following:\n\n* CR as defined above\n* Normal free light chain ratio\n* Absence of clonal cells in the bone marrow by immunohistochemistry or immunofluorescence","groups":[{"description":"Granix on Day -7 through Day -2.\n\nHDM intravenously (IV) on Day -2.\n\nAutologous stem cell transplantation on Day 0","id":"OG000","title":"Experimental: Granix and High Dose Melphalan (HDM)"},{"description":"HDM intravenously (IV) on Day -2.","id":"OG001","title":"Control: High Dose Melphalan (HDM)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Day +100","title":"Number of Participants With Complete Response or Stringent Complete Response","type":"PRIMARY","unitOfMeasure":"Participants"}